2455
0
Loading version...
🔄 Update App
🔍 Check for Updates
Test Notification
🔔 Enable Notifications
📰 Fetch NHK News
🚀 Fetch TechCrunch News
🧪 Experiment
📰 Article Management
📚 Reading List
🎤 Speaking List
📊 Statistics
💻 Software Statistics
Push Admin
Edit Reading
Back to List
Basic Information
Title
Please enter a title.
URL
Please enter a valid URL.
Date
カテゴリID
画像ファイル名
統計情報
単語数:
145語
読了回数:
0回
作成日:
2022/05/16 23:20
更新日:
2025/12/09 16:19
本文
本文
Osaka-based pharmaceutical company Shionogi says it has started a clinical trial for Japanese adolescents aged 12 to 19 of a coronavirus vaccine it is developing for all age groups. The product is a recombinant protein-based vaccine. For adult usage, the company is set to apply for approval with Japanese authorities as early as next month. The company said on Monday the clinical trial involves 350 adolescents. They will receive two doses to see whether their neutralizing antibody levels will equal those found in adults who have received the shots, or rise even higher. The trial began last Saturday. The drugmaker says the participants will receive a third dose to see whether their antibody levels rise again. Shionogi also plans a clinical trial for children 5 to 11. The company says it "will seek to provide new options for COVID-19 vaccination for people of all ages."
本文を入力してください。
メモ
メモ・感想
キャンセル
更新
Debug Info:
Saved State:
-
Redirected Flag:
-
Current URL:
-
Refresh
Close
Debug
Send Report
Send Report
Draw Arrow
Clear
Message:
Cancel
Send
